Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation

Key Points

• The combination of oroxylin A and donafenib significantly enhances anti-tumor effects through TP53 activation.
• This synergy offers a viable alternative to donafenib alone, potentially improving treatment outcomes in hepatocellular carcinoma.
• The study shows that distinct molecular pathways can work together to combat cancer progression effectively.
• The findings underscore the need for further exploration in clinical settings to validate these promising results.